Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

Inclusion Criteria

• •1. Women aged 18 years and above with pathologically confirmed recurrent or metastatic advanced breast cancer ;
• •2. The patient has tumor specimens (formalin-fixed, paraffin-embedded or fresh pre-treated recurrent tumor tissue);
• •3. Patients who have failed standard treatment in the late stage;
• •4. At least one measurable lesion;
• •5. ECOG PS : 0-2 points;
• •6. Estimated survival period ≥12 weeks;
• •7. The function level of major organs meets the following standards:
• •1\) The blood routine examination standards must meet: ANC ≥1.5×109/L, PLT ≥75×109/L, Hb ≥85g/L (no blood transfusion and blood products within 14 days, no use of G-CSF and other hematopoietic stimulating factors for correction) 2) Biochemical examinations must meet the following standards: TBIL \<1.5×ULN, ALT, AST \<2.5×ULN, ALT, AST \<5×ULN for patients with liver metastasis, BUN and Cr ≤1×ULN or endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures, or have undergone a pregnancy test (serum or urine) within 7 days before enrollment, with a negative result, and are willing to use appropriate contraceptive methods during the trial and 8 weeks after the last administration of the trial drug.
• •9\. The subjects voluntarily join this study, have good compliance, and cooperate with follow-up.